NEWS DETAIL

KRYSTAL-10 di ESMO GI 2026: Adagrasib Plus Cetuximab vs Kemoterapi dalam mCRC Bermutasi KRAS G12C – Oncodaily

KRYSTAL-10 at ESMO GI 2026: Adagrasib Plus Cetuximab vs Chemotherapy in KRAS G12C-Mutated mCRC O…

Maklumat Perubatan July 8, 2026

Kandungan penuh artikel

KRYSTAL-10 at ESMO GI 2026: Adagrasib Plus Cetuximab vs Chemotherapy in KRAS G12C-Mutated mCRC / adagrasib plus cetuximab, cancer, cancer care, Cancer, adagrasib plus cetuximab, cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical trials, colorectal cancer, ESMO, ESMO GI 2026, ESMO GI Cancers Congress 2026, ESMO-GI, KRASG12C inhibitors, KRYSTAL-10, OncoDaily, Oncology

この記事に関連する商品

記事のタイトル、要約、本文から関連性の高い商品を自動的に表示しています。

よくある質問

Which products are related to this article?

The system matched these relevant products from the article content: ADADX アダグラシブ、Lucius Adagrasib をオンラインで購入する.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.